125 related articles for article (PubMed ID: 20545479)
21. Contrast-induced nephropathy and risk of acute kidney injury and mortality after cardiac operations.
Garcia S; Ko B; Adabag S
Ann Thorac Surg; 2012 Sep; 94(3):772-6. PubMed ID: 22835553
[TBL] [Abstract][Full Text] [Related]
22. Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction.
Lucreziotti S; Centola M; Salerno-Uriarte D; Ponticelli G; Battezzati PM; Castini D; Sponzilli C; Lombardi F
Int J Cardiol; 2014 Jun; 174(1):37-42. PubMed ID: 24698233
[TBL] [Abstract][Full Text] [Related]
23. ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy.
Umruddin Z; Moe K; Superdock K
J Nephrol; 2012; 25(5):776-81. PubMed ID: 22322819
[TBL] [Abstract][Full Text] [Related]
24. The incidence of contrast-induced nephropathy in trauma patients.
Hipp A; Desai S; Lopez C; Sinert R
Eur J Emerg Med; 2008 Jun; 15(3):134-9. PubMed ID: 18460952
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for hemodialysis and mortality in patients with contrast-induced nephropathy.
Lai HM; Aronow WS; Chugh SS; Pudasaini B; Goel A; Garrick R
Am J Ther; 2013; 20(6):607-12. PubMed ID: 22820714
[TBL] [Abstract][Full Text] [Related]
26. The changing definition of contrast-induced nephropathy and its clinical implications: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Slocum NK; Grossman PM; Moscucci M; Smith DE; Aronow HD; Dixon SR; Share D; Gurm HS
Am Heart J; 2012 May; 163(5):829-34. PubMed ID: 22607861
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
Bilasy ME; Oraby MA; Ismail HM; Maklady FA
J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
[TBL] [Abstract][Full Text] [Related]
28. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
Oguzhan N; Cilan H; Sipahioglu M; Unal A; Kocyigit I; Kavuncuoglu F; Arikan T; Akpek M; Elcik D; Sahin O; Gulme E; Pala C; Tokgoz B; Utas C; Oguzhan A; Oymak O
Ren Fail; 2013; 35(4):434-9. PubMed ID: 23413781
[TBL] [Abstract][Full Text] [Related]
29. Sodium bicarbonate versus normal saline for protection against contrast nephropathy.
Budhiraja P; Chen Z; Popovtzer M
Ren Fail; 2009; 31(2):118-23. PubMed ID: 19212908
[TBL] [Abstract][Full Text] [Related]
30. A randomized trial of saline hydration to prevent contrast-induced nephropathy in patients on regular captopril or furosemide therapy undergoing percutaneous coronary intervention.
Shemirani H; Pourrmoghaddas M
Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):280-5. PubMed ID: 22382219
[TBL] [Abstract][Full Text] [Related]
31. Platelet-to-Lymphocyte Ratio Predicts Contrast-Induced Nephropathy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.
Kocas C; Yildiz A; Abaci O; Karaca OS; Firdin N; Dalgic Y; Bostan C; Ersanli M
Angiology; 2015 Nov; 66(10):964-8. PubMed ID: 25852211
[TBL] [Abstract][Full Text] [Related]
32. Incidence of contrast-induced nephropathy in kidney transplant recipients.
Haider M; Yessayan L; Venkat KK; Goggins M; Patel A; Karthikeyan V
Transplant Proc; 2015 Mar; 47(2):379-83. PubMed ID: 25769577
[TBL] [Abstract][Full Text] [Related]
33. Renal safety and angiotensin II blockade medications in patients undergoing non-emergent coronary angiography: a randomized controlled study.
Wolak T; Aliev E; Rogachev B; Baumfeld Y; Cafri C; Abu-Shakra M; Novack V
Isr Med Assoc J; 2013 Nov; 15(11):682-7. PubMed ID: 24511648
[TBL] [Abstract][Full Text] [Related]
34. Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
Barbieri L; Verdoia M; Schaffer A; Cassetti E; Marino P; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):181-6. PubMed ID: 25315668
[TBL] [Abstract][Full Text] [Related]
35. The use of nitrates in the prevention of contrast-induced nephropathy in patients hospitalized after undergoing percutaneous coronary intervention.
Peguero JG; Cornielle V; Gomez SI; Issa OM; Heimowitz TB; Santana O; Goldszer RC; Lamas GA
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):310-4. PubMed ID: 24367008
[TBL] [Abstract][Full Text] [Related]
36. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention.
Nyman U; Björk J; Aspelin P; Marenzi G
Acta Radiol; 2008 Jul; 49(6):658-67. PubMed ID: 18568558
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for contrast-induced nephropathy and their association with mortality in patients with blunt splenic injuries.
Hsieh TM; Tsai TH; Liu YW; Hsieh CH
Int J Surg; 2016 Nov; 35():69-75. PubMed ID: 27622729
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial.
Erol T; Tekin A; Katırcıbaşı MT; Sezgin N; Bilgi M; Tekin G; Zümrütdal A; Sezgin AT; Müderrisoğlu H
Int J Cardiol; 2013 Aug; 167(4):1396-9. PubMed ID: 22572633
[TBL] [Abstract][Full Text] [Related]
39. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
[TBL] [Abstract][Full Text] [Related]
40. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
